Gilead Sciences, a biopharmaceutical company, has begun the second phase of researching hypertrophic cardiomyopathy treatment. This study includes using HCM treatment candidate eleclazine as well as the iRhythm Zio Patch, a cardio monitoring patch. Researchers are looking to measure changes in arrhythmic burden assessments as a result of the treatment. Read more here and find out more from iRhythm here.
Study underway to test treatment for HCM
Posted on Apr 21, 2016